NHS Cancer Waiting Times Hit 18-Month High

More than 300,000 patients in England are currently waiting longer than the 62-day NHS target to begin cancer treatment following an urgent referral, according to NHS England performance data — the highest backlog recorded in the past 18 months. The figures represent a deepening crisis in oncology services that clinicians and health policy analysts warn could affect long-term survival outcomes if left unaddressed.

The 62-day standard, which requires that patients with suspected cancer begin treatment within two months of an urgent GP referral, is one of the most closely watched benchmarks in the NHS. Performance against this target has deteriorated significantly in recent months, with NHS England data showing that only around 67 percent of patients are currently being treated within the standard — well below the 85 percent operational target set by NHS England. (Source: NHS England)

The Scale of the Current Backlog

The latest NHS England performance data indicate that the number of patients waiting more than 62 days for cancer treatment following an urgent referral has climbed to levels not seen since early last year. The trend is particularly pronounced in specific tumour pathways, including lower gastrointestinal, urology, and gynaecological cancers, where diagnostic bottlenecks and limited treatment capacity have compounded existing pressures.

Pathways Under the Greatest Strain

Lower gastrointestinal cancer pathways — covering bowel and colorectal cancers — are among those experiencing the sharpest deterioration, officials said. Endoscopy capacity constraints have been cited as a primary driver, with colonoscopy waiting lists remaining extended despite targeted investment. Urology services, encompassing prostate and bladder cancer referrals, face similar demand pressures, with consultant shortages limiting throughput across multiple NHS trusts.

NHS England has acknowledged the performance shortfall and confirmed that recovery plans are being developed at integrated care board level, though critics argue that system-wide reform is needed rather than trust-by-trust interventions. For further context on broader NHS capacity pressures affecting patient outcomes, see our reporting on NHS Waiting Times Hit Record High as Staff Shortages Worsen.

What Is Driving the Delays

Health system analysts point to a convergence of structural and operational factors that have pushed cancer waiting times to their current levels. Workforce shortages, diagnostic infrastructure gaps, and sustained high demand following post-pandemic referral surges are widely cited as the principal contributors.

Workforce Pressures Across the Cancer Pathway

The NHS in England is currently operating with a shortfall of several thousand oncologists, radiologists, and specialist nurses, according to NHS workforce data and Royal College reports. The diagnostic workforce — pathologists, radiographers, and endoscopists in particular — has been flagged by NHS England's own Long Term Workforce Plan as critically undersupplied relative to projected demand. Without adequate diagnostic staffing, patients awaiting cancer investigations face extended waits before their referrals can be processed, let alone treated. This workforce dimension intersects directly with the broader GP referral pipeline, a problem examined in detail in our coverage of NHS Waiting Times Hit Record High as GP Shortages Worsen.

The Diagnostic Bottleneck

NICE guidelines emphasise the importance of completing diagnostic investigations within 28 days of an urgent suspected cancer referral — the so-called Faster Diagnosis Standard. NHS England data show that performance against this standard has also deteriorated, with a growing proportion of patients not receiving a definitive diagnosis within the recommended timeframe. (Source: NHS England, NICE) Inadequate MRI and CT scanner capacity, combined with radiologist shortages, means that even where referrals are triaged promptly, imaging backlogs can delay the diagnostic process by several weeks.

Impact on Patient Outcomes

The clinical consequences of extended cancer waiting times are well-evidenced in peer-reviewed literature. A BMJ analysis of treatment delay data found statistically significant associations between delayed cancer treatment and reduced five-year survival rates across multiple cancer types, including breast, lung, and colorectal cancers. The Lancet has similarly published modelling data suggesting that diagnostic delays during periods of system strain translate into measurable increases in avoidable cancer mortality at a population level. (Source: BMJ, The Lancet)

Stage at Diagnosis and Survival

One of the most significant clinical concerns associated with waiting time delays is the risk of disease progression between referral and diagnosis or treatment. Cancers detected at an earlier stage are substantially more amenable to curative treatment. NHS data indicate that approximately 54 percent of cancers in England are currently diagnosed at stage one or two — a figure that has improved over recent decades but that clinicians warn could stagnate or reverse if diagnostic access is not protected. (Source: NHS England) The WHO has identified early diagnosis as one of the most cost-effective interventions in cancer control, reinforcing the public health case for meeting waiting time standards.

Despite the current pressures, it is important to note that NHS cancer survival rates have improved significantly over the longer term, as documented in our reporting on NHS Cancer Survival Rates Hit Record High. The current waiting time deterioration represents a disruption to a trajectory of overall improvement rather than a fundamental reversal of progress.

Government and NHS Response

NHS England has confirmed that cancer recovery remains a stated priority within its elective recovery programme. Additional funding allocated to diagnostic hubs and community diagnostic centres — facilities designed to increase scanning and testing capacity outside of acute hospital settings — is intended to address some of the bottlenecks contributing to delays, officials said. More than 100 community diagnostic centres are currently operational across England, collectively delivering millions of additional tests and scans annually, according to NHS England. (Source: NHS England)

The government has also reaffirmed its commitment to the NHS Long Term Workforce Plan, which sets out ambitions to train significantly more doctors, nurses, and allied health professionals over the coming decade. Critics, however, including the British Medical Association and Cancer Research UK, have argued that the pace of workforce expansion is insufficient to meet current demand pressures in the near term.

What the Targets Mean and Why They Matter

The 62-day standard is not arbitrary. It was developed on the basis of clinical evidence suggesting that delays beyond two months between urgent referral and treatment initiation are associated with measurable increases in harm. The 28-day Faster Diagnosis Standard was introduced more recently, recognising that the diagnostic phase — not just the treatment phase — is a critical window in which early-stage disease can progress. Both standards are monitored by NHS England and published monthly, allowing for public accountability. (Source: NHS England, NICE)

How the UK Compares Internationally

International comparisons of cancer waiting times are methodologically complex due to differences in how countries define and measure referral-to-treatment pathways. However, data from the Organisation for Economic Co-operation and Development and WHO indicate that several comparable health systems, including those in Scandinavia and the Netherlands, achieve higher rates of compliance with equivalent diagnostic and treatment benchmarks. Health policy researchers have pointed to centralised diagnostic networks and stronger primary care gatekeeping as factors that contribute to faster pathway progression in those systems. (Source: WHO)

What Patients Can Do

While the responsibility for meeting waiting time standards lies with NHS commissioners and providers, individuals can take steps to support early detection and ensure that potential cancer symptoms are investigated without delay. Health authorities including NHS England and NICE emphasise the importance of recognising warning signs and seeking prompt medical advice.

• Report any unexplained or persistent changes in your body to your GP as soon as possible — do not wait to see if symptoms resolve on their own
• Be aware of key cancer warning signs: unexplained weight loss, persistent fatigue, new or changing lumps, blood in urine or stool, persistent cough, changes in bowel habits, or difficulty swallowing
• If referred urgently by your GP, ask about the expected timeline and the specific pathway you are on
• If you have not heard from a specialist within two weeks of an urgent referral, contact your GP practice for a status update
• Attend all NHS cancer screening appointments for which you are eligible — bowel, breast, and cervical screening programmes are designed to detect cancer at an earlier, more treatable stage
• Maintain an accurate record of your symptoms, including when they started and how they have changed, to assist clinicians during appointments
• Do not delay seeking help due to concerns about burdening the NHS — early presentation consistently improves outcomes

For patients seeking information on historical NHS cancer performance data and the long-term trajectory of waiting times, our earlier coverage of NHS Cancer Waiting Times Hit Record High provides additional statistical context and analysis of the factors that have shaped the current situation.

Outlook

NHS England has indicated that integrated care boards are required to submit cancer recovery trajectories outlining how trusts plan to return to operational targets within defined timeframes. However, health analysts and clinical leaders have cautioned that without sustained investment in diagnostic workforce, physical infrastructure, and primary care capacity, recovery plans risk being undermined by continued high demand. The intersection of GP access pressures and downstream hospital pathway performance remains a critical system-wide challenge, a dynamic explored further in our reporting on NHS waiting lists hit record high as GP shortages worsen.

The evidence base from the BMJ, The Lancet, and NHS England is consistent: timely cancer diagnosis and treatment saves lives, and every week of unnecessary delay carries measurable clinical risk. Whether the current trajectory of deterioration can be reversed without structural reform of diagnostic and treatment capacity remains an open and urgent question for health system leaders and policymakers. (Source: BMJ, The Lancet, NHS England)